This guide is part of the PlexusDx Education Hub, our home for GLP-1 science, weight-management protocols, and the genetics that shape metabolic outcomes
The glucose-lowering mechanisms of action of GLP-1RAs are well-characterized
SCALE found improvements in such cardiometabolic risk markers as lipid profile, blood pressure, and glycaemic control [82, 83], consolidated by pooled analysis in older and younger adults [84]
PubMed Central, Yang, Qin, and Guo-Wei He
Abbreviations DPP-4: Dipeptidyl peptidase-4 Ex9: Exendin-[939] Gcg RA Null : Gcg null mouse model Gcg RA PDX1Cre : Mouse model with Gcg reactivated in the pancreas Gcg RA VilCre : Mouse model with Gcg reactivated in the intestine GIP: Glucose-dependent insulinotropic polypeptide GIPrAB: GIP receptor-antagonising antibody GLP-1: Glucagon-like peptide-1 GLP-1R: GLP-1 receptor PDX1: Pancreatic duodenal homeobox-1 PDX1Cre: Wild-type littermate of Gcg RA PDX1Cre VilCre: Wild-type littermate of Gcg RA VilCre References Fujioka K, ONeil PM, Davies M et al (2016) Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers
Inspectors check ingredient sourcing, sterility protocols, and labeling accuracy, similar to inspections of pharmaceutical manufacturers
